# Clinical Trials Data BRAF - Document 14

# Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01719380

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Metastatic colorectal cancer\n\* Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens\n\* Life expectancy \u2265 3 months\n\* ECOG performance status \u2264 2\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Patients with clinically manifested diabetes\n\* Acute or chronic pancreatitis\n\* Clinically significant cardiac disease\n\nOther protocol-defined inclusion/exclusion criteria may apply.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria, it has not been specified that a BRAF gene mutation affects eligibility for this clinical trial. The criteria do not mention genetic mutations as a factor for inclusion or exclusion. Therefore, having a BRAF gene mutation alone would not make a patient ineligible, as long as they meet all the other inclusion criteria and none of the exclusion criteria apply.